title: Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients.
abstract: The course of left ventricular hypertrophy was investigated in anemic hemodialysis patients treated with recombinant human erythropoietin (r-huEPO). 12 patients, aged 60.8 +/- 9.9 years (mean +/- SD) were treated for 18.8 +/- 2.7 months. Left ventricular size was estimated by echocardiography performed before treatment and at least 12 months after relieving anemia. Patients had signs of left ventricular and/or asymmetric septal hypertrophy when compared with a nonanemic and normotensive control group matched for sex and age. At baseline, hemoglobin (Hb) was 8.6 +/- 0.7 g/dl; interventricular septum thickness (IVST) was 1.75 +/- 0.34 cm, left ventricular posterior wall thickness (LVPWT) 1.32 +/- 0.19 cm, left ventricular muscle mass index (LVMI) 222.7 +/- 41 g/m2 and blood pressure (BP) 146.4 +/- 10/81.6 +/- 6 mm Hg. Hb rose to 11.4 +/- 1.2 g/dl (p less than 0.001); IVST and LVMI decreased to 1.42 +/- 0.35 cm (p less than 0.02) and 155.4 +/- 25.1 g/m2 (p less than 0.001); LVPWT and BP remained unchanged (1.30 +/- 0.26 cm and 146.8 +/- 16.9/81.2 +/- 7.8 mm Hg) at the end of the study. During the observation period, two groups of 5 and 7 patients differed from each other. The group of 5 patients had higher BP values (158.9 +/- 9.8/86.5 +/- 5.3 vs. 140.0 +/- 9.5/79.2 +/- 6.8 mm Hg, p less than 0.01), and the period with Hb values above 10 g/dl was shorter (14.5 +/- 2.4 vs. 17.8 +/- 2.4 months, p less than 0.05). These 5 patients failed to show a significant decrease in IVST and LVMI.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Kantonsspital Aarau, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Zehnder
authors.forename: M
authors.initials: M
authors.lastname: Zuber
authors.forename: M
authors.initials: M
authors.lastname: Sulzer
authors.forename: B
authors.initials: B
authors.lastname: Meyer
authors.forename: E
authors.initials: E
authors.lastname: Straumann
authors.forename: H R
authors.initials: HR
authors.lastname: Jenzer
authors.forename: A
authors.initials: A
authors.lastname: Blumberg
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000740:Anemia / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D001794:Blood Pressure; D006332:Cardiomegaly / Q000000981:diagnostic imaging / Q000209:etiology / Q000503:physiopathology*; D004452:Echocardiography; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006352:Heart Ventricles; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D012016:Reference Values; D006435:Renal Dialysis / Q000009:adverse effects*; D013997:Time Factors; D016277:Ventricular Function, Left
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin